


# Mundipharma-sponsored symposium: Optimising management of critically ill patients with invasive fungal disease

Monday 24 October 2022, 12:30–13:30 CEST  
Room 253, Level 2,  
Palais des Congrès - Porte Maillot, Paris, France



Dear colleagues,

It gives me great pleasure to invite you to the Mundipharma-sponsored satellite symposium, titled 'Optimising management of critically ill patients with invasive fungal disease'.

Invasive fungal disease (IFD) is associated with increased morbidity and mortality, and is therefore increasingly being recognised as a threat in critically ill patients. Prompt diagnosis and early initiation of antifungal therapies are critical in the successful treatment and management of IFD. During this symposium, the esteemed faculty will discuss how to improve treatment outcomes in critically ill patients with IFD, highlighting the use of biomarkers for early management and diagnosis. They will then examine challenges in managing fungal infections in immunosuppressed patients in the intensive care unit (ICU).

Finally, the faculty will provide an overview of the treatment challenges associated with intra-abdominal candidiasis in the ICU and how these concerns may be addressed using future solutions.

We look forward to welcoming you to this informative and educational session.

**Professor Ignacio Martin-Loeches (Chair)**

Time (CEST)	Optimising management of critically ill patients with IFD
12:30	<b>Welcome and introduction</b> Professor Ignacio Martin-Loeches
12:35	<b>Optimising biomarkers to improve outcomes in critically ill patients</b> Professor Andrea Cortegiani
12:50	<b>Key challenges in managing fungal infections in immunosuppressed critically ill patients</b> Professor Jean-Paul Mira
13:05	<b>Intra-abdominal candidiasis in the ICU; current challenges and future directions</b> Professor Pedro Póvoa
13:20	<b>Q&amp;A session and panel discussion</b> All faculty

Meet the faculty



[Back to the agenda](#)



**Professor Ignacio Martin-Loeches**

*Clinical Professor, Clinical Medicine,  
School of Medicine, Trinity College Dublin,  
Dublin, Ireland*

**Professor Andrea Cortegiani**

*Associate Professor, Department of Surgical,  
Oncological and Stomatological Science,  
Università degli Studi di Palermo,  
Palermo, Italy*



**Professor Jean-Paul Mira**

*Head of the Medical Intensive Care Unit,  
Groupe Hospitalier Paris Centre, Cochin University  
Hospital, AP-HP, Paris Cité University, Paris, France*



**Professor Pedro Póvoa**

*Dept of Intensive Care, CHLO, Lisbon, Portugal;  
Full Professor of Medicine, NOVA Medical School,  
New University of Lisbon, Lisbon, Portugal*



Mundipharma is a global healthcare company dedicated to bringing innovative treatments to patients in the areas of infectious diseases, pain and supportive care, consumer healthcare and other severe and debilitating diseases.

Mundipharma's guiding principles, centred around integrity and patient centricity, are at the heart of everything we do.